Recently, pharmaceutical giant Eli Lilly announced the acquisition of private biotechnology company Kelonia Therapeutics for up to $7 billion, aiming to obtain a new generation CAR-T (a cancer immunotherapy) technology that does not require in vitro modification of immune cells, in order to seize the opportunity in the field of "in vivo gene therapy".
